Into the valley of death: research to innovation
- PMID: 23402848
- DOI: 10.1016/j.drudis.2013.01.012
Into the valley of death: research to innovation
Abstract
The phase between research and successful innovation is known as the valley of death. Increasingly, researchers from the pharmaceutical industry and academia are working together, often encouraged by governments, to cross this 'valley' as they seek to bring basic research to the market. This is consistent with newer models of innovation policy that stress interaction between the different agents across the innovation process. Here, we examine this interaction in the UK, the EU and the USA using several specific examples, suggesting that cooperation is still far from perfect and that the return for academia on its research investment is relatively small. Countries are also beginning to use research as a tool of industrial economic policy.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.Drug Discov Today. 2012 Nov;17(21-22):1242-8. doi: 10.1016/j.drudis.2012.04.004. Epub 2012 Apr 12. Drug Discov Today. 2012. PMID: 22521665 Review.
-
[Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].Lakartidningen. 2012 Jun 27-Jul 17;109(26-28):1280-1. Lakartidningen. 2012. PMID: 22852257 Swedish. No abstract available.
-
Safeguarding innovation through an economic downturn.Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):347-9. doi: 10.1586/erp.10.35. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 20715908 No abstract available.
-
An audience with...Francis Collins. Interviewed by Asher Mullard.Nat Rev Drug Discov. 2011 Jan;10(1):14. doi: 10.1038/nrd3357. Epub 2010 Dec 10. Nat Rev Drug Discov. 2011. PMID: 21151031 No abstract available.
-
Drug discovery: new models for industry-academic partnerships.Drug Discov Today. 2009 Jan;14(1-2):95-101. doi: 10.1016/j.drudis.2008.10.003. Epub 2008 Nov 21. Drug Discov Today. 2009. PMID: 18992364 Review.
Cited by
-
Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions.ACS Infect Dis. 2022 Mar 11;8(3):557-573. doi: 10.1021/acsinfecdis.1c00570. Epub 2022 Feb 22. ACS Infect Dis. 2022. PMID: 35192346 Free PMC article.
-
The Medicinal Chemistry in the Era of Machines and Automation: Recent Advances in Continuous Flow Technology.J Med Chem. 2020 Jul 9;63(13):6624-6647. doi: 10.1021/acs.jmedchem.9b01956. Epub 2020 Feb 21. J Med Chem. 2020. PMID: 32049517 Free PMC article. Review.
-
The price of progress: Funding and financing Alzheimer's disease drug development.Alzheimers Dement (N Y). 2018 Jun 13;4:330-343. doi: 10.1016/j.trci.2018.04.008. eCollection 2018. Alzheimers Dement (N Y). 2018. PMID: 30175227 Free PMC article.
-
Metal Sulfide Nanoparticle Synthesis with Ionic Liquids - State of the Art and Future Perspectives.ChemistryOpen. 2021 Feb;10(2):272-295. doi: 10.1002/open.202000357. ChemistryOpen. 2021. PMID: 33751846 Free PMC article. Review.
-
Molecular genetics to genomic medicine practice: at the heart of value-based delivery of healthcare.Mol Genet Genomic Med. 2013 May;1(1):4-6. doi: 10.1002/mgg3.8. Mol Genet Genomic Med. 2013. PMID: 24498597 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources